Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
Background: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...
Main Authors: | Simon Rauch, Dominic Fong, Elisa Morra, Francesca Maines, Orazio Caffo, Gilbert Spizzo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | Prostate International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888215301057 |
Similar Items
-
Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01) -
Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01) -
A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
by: Takashi Kawahara, et al.
Published: (2020-09-01) -
Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: ZhenHeng Wei, et al.
Published: (2021-08-01) -
The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)